Table 3. Response status to Imatinib treatment among newly diagnosed patients’ with chronic myeloid leukemia at Tikur Anbessa Specialized Hospital from October 1, 2016- November 30, 2017.
| Duration of Imatinib Treatment | Response Status based on baseline WBC category*, n (%) |
||||||
|---|---|---|---|---|---|---|---|
| ≤50k | 51-100k | 101-150k | ≥151k | Total | p-value | ||
| 2 weeks# | CHR | 27(93.1) | 0 | 2(6.9) | 0 | 29(22.8) | |
| No CHR | 34(40.5) | 23(27.4) | 14(16.6) | 13(15.5) | 84(66.1) | ||
| WBC increased from baseline** | 5(35.7) | 6(42.9) | 0 | 3(21.4) | 14(11.1) | ||
| Total | 66(52.0) | 29(22.8) | 16(12.5) | 16(12.5) | 127 | <0.0001a | |
| 1 month# | CHR | 50(68.5) | 11(15.1) | 7(9.6) | 5(6.8) | 73(60.3) | |
| No CHR | 18(37.5) | 15(31.3) | 5(10.4) | 10(20.8) | 48(39.7) | ||
| Total | 68(56.2) | 26(21.5) | 12(9.9) | 15(12.4) | 121 | 0.004 | |
| 2 months | CHR | 52(55.9) | 22(23.7) | 9(9.7) | 10(10.7) | 93(78.8) | |
| No CHR | 10(40.0) | 5(20.0) | 5(20.0) | 5(20.0) | 25(21.2) | ||
| Total | 62(52.5) | 27(22.9) | 14(11.9) | 15(12.7) | 118 | 0.245 | |
| 3 months | CHR | 74(56.1) | 28(21.2) | 14(10.6) | 16(12.1) | 132(91.7) | |
| No CHR | 7(58.3) | 2(16.7) | 3(25.0) | 0 | 12(8.3) | ||
| Total | 81(56.3) | 30(20.8) | 17(11.8) | 16(11.1) | 144 | 0.320 a | |
*White blood cell count x 103 cells/ mm3 found at time of initiation of Imatinib treatment.
**White blood count increased as compared to the preceding complete count test findings and also is part of no CHR category.
# Significant at p<0.05
a If fisher exact test is employed, otherwise χ2 test is used.